M

Mesoblast Limited

D
MESO
USD
-0.09
(-1.0321%)
Market Closed
4,489.00
Volume
-0.7215
EPS
-
Div Yield
-9.685746
P/E
985,359,686.93
Market Cap
Today
-2.5409%
1 Week
3.106%
1 Month
-13.700%
6 Months
8.010%
12 Months
224.436%
Year To Date
299.537%
All Time
103.378%

Title:
Mesoblast Limited

Sector:
Healthcare
Industry:
Biotechnology
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Do you need help or have a question?